Komori
PRISM BioLab (206A) · InitiativeAdvanced

Program Selection and Resource Allocation Based on Clear Objectives and Deadlines

First written in FY2024. 2 of 3 entries say "Advanced", first in FY2025. Latest entry: 2026-05-14.

3entries
3years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024AdvancedFY2025 – 2026-05-142024: 12025: 120252026: 12026
Same theme, other companies
Allocation of R&D resources through a focused strategyA theme 5 companies write about · 0 as a headwind · 5 as a tailwind

0 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. 2026-05-14AdvancedEarnings

    「Although one program at the “hit compound discovery” stage was discontinued because it did not meet the criteria for hit compound qualification, two programs successfully generated hit compounds in January and April 2026, respectively, and advanced to the “lead compound discovery” stage.」

    The discontinuation of a program and the generation of hit compounds in 2 programs, followed by advancement to a higher stage, were reported together, specifically demonstrating the company’s screening and resource reallocation process.
  2. FY2025AdvancedAnnual report

    「Not all of these programs advance to later stages. Some are discontinued because the target compound cannot be obtained with a certain probability. Advancing programs requires substantial resources, including researchers and funding, which limits the number of programs that can be pursued in parallel at any given time.」

    A selection policy that prioritizes promising programs under resource constraints, based on stage transitions and discontinuation, is being implemented through actual program discontinuations and new launches.
  3. FY2024First statedAnnual report

    「We place importance on prioritizing the allocation of resources to programs with a high likelihood of success and out-licensing. We establish clear targets and timelines when initiating programs and may discontinue a program if unexpected circumstances arise as it progresses.」

    The company seeks to optimize its pipeline through selection, including discontinuation, rather than simply advancing programs to later stages.
Moved together

"Continuation of the Phase II clinical trial of PRI-724 in fibrosis" moved the same way as this thread, in the same document, in 2 of its 3 moves.

22222★12345
  1. ★This thread
  2. 1Continuation of the Phase II clinical trial of PRI-724 in fibrosis2×
  3. 2Hybrid model combining in-house and joint development businesses2×
  4. 3Maintaining multiple in-house drug discovery programs and continuously selecting new targets2×
  5. 4Milestone and Royalty Income Through Partnerships with Pharmaceutical Companies2×
  6. 5Recurring Monetization of Drug Discovery Platform Technologies2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for PRISM BioLab yet. It last moved in the Earnings of 2026-05-14: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.